Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Patrick K. Reville"'
Autor:
Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Cl
Externí odkaz:
https://doaj.org/article/56d8bd49a94b4312b631a820fc45bb9c
Autor:
Lianchun Xiao, Sanam Loghavi, Marina Konopleva, Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Gheath Alatrash, Elias Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, Caitlin R. Rausch, Hagop M. Kantarjian, Maro Ohanian, Jorge E. Cortes, Farhad Ravandi
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Autor:
Patrick K. Reville, Tapan M. Kadia
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology
Frontiers in Oncology
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes. Despite these advances, even in patients that achieve a complete remission with initial
Autor:
Michael R. Green, Maomao Ding, Hussein A. Abbas, Marina Konopleva, Praveen Barrodia, James P. Allison, Latasha Little, Jairo T. Mathews, Dapeng Hao, Sreyashi Basu, Naval Daver, Jin Seon Im, Katarzyna Tomczak, Padmanee Sharma, Kunal Rai, Guillermo Garcia-Manero, Jing Ning, Andrew Futreal, Patrick K. Reville, Steven M. Kornblau, Linghua Wang, Jianhua Zhang, Gheath Alatrash
Publikováno v:
Cancer Immunology Research. 9:PR003-PR003
Introduction: Allogeneic hematopoietic stem cell transplantation (ASCT) remains the only curative option for patients with relapsed/refractory (R/R) AML, achieved via the grafted T cells versus leukemia effect. Since ASCT is not viable option to many
Autor:
Elisabeth Paietta, Fangxin Hong, Brad S. Kahl, Kyung Mann Kim, Vaishalee P. Kenkre, Bartosz Grzywacz, Erik A. Ranheim, Patrick K. Reville, Lakeesha Carmichael, Eneida A. Mendonça, Amy K. Erbe, Wei Wang, Paul M. Sondel, Sandra J. Horning, Anna Hoefges, Yiqiang Song, Songwon Seo, Jeffrey S. Miller, Randy D. Gascoyne, Jacquelyn A. Hank
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-
Autor:
Susan L. Cohn, Stephen D. Gillies, Ralph A. Reisfeld, Julie R. Park, Wei Wang, Alice L. Yu, M. Fevzi Ozkaynak, Patrick K. Reville, Jacquelyn A. Hank, Michael D. Hogarty, Wendy B. London, Andrew L. Gilman, Paul M. Sondel, Yiqiang Song, Arlene Naranjo, Lakeesha Carmichael, Mitchell B. Diccianni, Amy K. Erbe, John M. Maris, Katherine K. Matthay, Dustin Hess, KyungMann Kim, Eneida A. Mendonça
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 1
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re
Autor:
Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Paul M. Sondel
Publikováno v:
Frontiers in Immunology
Frontiers in immunology, vol 8, iss JUN
Frontiers in Immunology, Vol 8 (2017)
Frontiers in immunology, vol 8, iss JUN
Frontiers in Immunology, Vol 8 (2017)
Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported as
Autor:
Lakeesha Carmichael, Amy K. Erbe, Paul M. Sondel, Michael D. Hogarty, Julie R. Park, Wei Wang, Patrick K. Reville, Mitchell B. Diccianni, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, KyungMann Kim, Alice L. Yu
Publikováno v:
Cancer Research. 77:LB-048
Introduction: High-risk neuroblastoma (NBL) patients (pts) enrolled in a COG Phase 3 clinical trial (ANBL0032) were randomized to isotretinoin (RA) alone or Immunotherapy: dinutuximab (anti-GD2 mAb) + IL2 + GMCSF + RA (Yu et al., NEJM, 2010). Dinutux